BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Voclera voclosporin regulatory update

Paladin submitted an NDS to Health Canada for Voclera voclosporin to treat moderate to severe psoriasis. Paladin has rights from Isotechnika to the transisomer of a cyclosporine analog that inhibits calcineurin in Canada,...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >